Results 121 to 130 of about 58,504 (176)

UGT1A1 and irinotecan: Ready for routine pharmacogenetic care. [PDF]

Br J Clin Pharmacol
Swen JJ.
europepmc   +1 more source

Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1. [PDF]

Oncogene
Erkan EP, Hämäläinen E, Kolikova J, Nikupaavola T, Sajnani K, Kuc K, Ojala K, Kukkonen M, Hermelo I, Kurttila A, Koskensalo S, Tarvainen T, Leppä A, Keränen I, Haapamäki C, Karjalainen E, Carpelan-Holmström M, Renkonen-Sinisalo L, Koskenvuo L, Puolakkainen P, Mecklin JP, Väyrynen JP, Virolainen E, iCAN, Nykter M, Aaltonen LA, Urbanucci A, Lepistö A, Ristimäki A, Seppälä TT.   +29 more
europepmc   +1 more source

Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial. [PDF]

BMC Cancer
Chen H, Jiang T, Wang H, Zheng J, Du B, Weng X, Yao N, Zhu Y, Liu Q, Lin F, Wang X, Lin X.   +11 more
europepmc   +1 more source

Irinotecan-Loaded Vaterite Microspheres for Drug Delivery: Drug Release and Dissolution Kinetics and Mechanism in an Aqueous Solution and Human Serum. [PDF]

Langmuir
Milner MP, Saint HA, Yang JM, Neumann CCM, Wansch K, Compton RG.   +5 more
europepmc   +1 more source

Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. [PDF]

J Clin Oncol
Al-Samkari H, Shatzel JJ, Panch SR, Keating JH, Walsh EP, Weekes CD, Kardosh A, Cohen SA, Cohen JJ, Hodges PG, Dhaver SE, Strojny N, Donovan C, Belibasakis C, Soff GA.   +14 more
europepmc   +1 more source

Case Report: cytoreductive prostatectomy after platinum-etoposide chemotherapy for <i>de novo</i> metastatic prostatic small cell neuroendocrine carcinoma. [PDF]

Front Urol
Wang Y, Wang Q, Yang H.
europepmc   +1 more source

Tumour cell density quantified by artificial intelligence is associated with differential benefit from irinotecan-based chemo-radiotherapy in locally advanced rectal cancer: a post-hoc study of the phase 3 ARISTOTLE trial. [PDF]

EBioMedicine
Shen Z, Brand D, Simard M, West NP, Lopes A, Begum R, Zhang Y, Royle G, Sebag-Montefiore D, Collins Fekete CA, Hawkins MA.   +10 more
europepmc   +1 more source

A Phase II Clinical Trial of Chemotherapy Rechallenge with or without Targeted Therapy in Refractory Metastatic Colorectal Cancer. [PDF]

Oncol Res
Wang C, Huang M, Li W, Sheng X, Zhao X, Zhu X, Chen Z, Zhang Z, Li H, Guo W.   +9 more
europepmc   +1 more source

IGFBP-3 enhances irinotecan efficacy in colorectal cancer <i>via</i> ROS-mediated apoptosis and β-catenin suppression. [PDF]

Res Pharm Sci
Gharehkhani E, Karami M, Bagheri A, Kukandeh MR, Shokrzadeh M.   +4 more
europepmc   +1 more source